CLGN - Collplant Biotechnologies Ltd logo

Collplant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd develops 3D bioprinting technologies and products for tissue regeneration and medical aesthetics. Its offerings include recombinant human collagen-based fillers, breast implants, wound care solutions, and bioinks for regenerative applications.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 10 years ago โ†’$21today

Score Overview

1 Year
Score
Net Growth-8.91%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-86.59%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.5
Net Growth-52x
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-97.97%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth-100.24%
Net Trend50%
Net Income Consistency
Rev Growth-93.36%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Collplant Biotechnologies Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CLGN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 3.67โ€”
1 Year2025-10-23
$ 22.75-83.87%
5 Years2021-10-22
$ 209.40-98.25%
10 Years2016-06-08
$ 178.95-97.95%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 318K-$ 12M$ 2M
2025$ 2M-$ 11M$ 5M
2024$ 515K-$ 16M$ 11M
2023$ 10M-$ 7M$ 26M
2022$ 299K-$ 16M$ 29M
2021$ 15M$ 237K$ 43M
2020$ 6M-$ 5M$ 3M
2019$ 2M-$ 11M$ 3M
IPO2018$ 4M-$ 6M$ 5M
CLGN - Collplant Biotechnologies Ltd logo

Collplant Biotechnologies Ltd fundamental performance

Across Collplant Biotechnologies Ltd's full reported history, from 2018 to 2025, revenue declined from $ 4M to $ 2M and net income went from -$ 6M to -$ 11M. Revenue increased in 50% of the years measured; net income in 50%.

Collplant Biotechnologies Ltd currently holds a 5-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.

Membership

Explore CLGN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies